Category REGENERATIVE MEDICINE

Stem Cell Therapy for Heart Failure

With modern, guideline-directed therapy,1 which includes angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), β-receptor blockers, mineralocorticoid receptor blockers, and angiotensin receptor neprilysin inhibitors, up to 40% of patients with dilated cardiomyopathy (heart failure with reduced ejection fraction) may experience a return of left ventricular ejection fraction (LVEF) and ventricular geometry to normal.2 This encouraging result

Read More


Study finds old brains still make neurons

https://www.nature.com/articles/s41591-019-0375-9 Reports of old brains’ decrepitude have been greatly exaggerated, scientists reported on Monday, unveiling results that contradict a much-discussed 2018 study and instead support the idea that human gray matter is capable of generating new neurons up to the ninth decade of life. The research, published in Nature Medicine, also found that old brains from

Read More


A special edition of The American Statistician presents over 40 papers on “Statistical inference in the 21st century: a world beyond P < 0.05”

Statistical significance has become an infallible doctrine of scientific research. However, many scientists and statisticians argue that long-held beliefs about statistical significance have, in fact, harmed the scientific community. In hypothesis testing, the p-value gives the probability or likelihood that the null hypothesis is true and is frequently used as a measure of “statistical significance.”

Read More


Hope for people with FOP disease as three drugs enter clinical trial – and one could be approved by next year

Fibrodysplasia ossificans progressiva (FOP) is a rare, genetic disease in which damaged muscle and soft tissue turn into bone It affects just 800 people worldwide and there is currently no known cure   Three drugs have entered clinical trials as potential treatments for the condition They target the genes and proteins responsible for the hyperactive bone growth

Read More


Microsoft, Oxford Biomedica to apply cloud, machine learning to improving gene therapy

The partnership between the US software giant and UK-based biotech company is designed to increase the yield and improve the purity of lentiviral vectors in gene therapy. A British cell and gene therapy company is partnering up with the world’s largest software company to improve gene therapy vectors using cloud computing and machine learning. Oxford,

Read More